
Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines
Led by Viking Global Investors, the Series B round will be used to bring Antheia’s first pharmaceutical compounds to market, expand its pipeline and scale production in global markets…